Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study.

Wei ZhangQian GuiJinnan ChenDazhong YuWenyu SuChangqing ZhuXiao LiangHong Lu

Published in: Helicobacter (2023)

The intravenous triple regimen, consisting of proton-pump inhibitor, metronidazole, and levofloxacin, could be considered in patients of H. pylori-associated peptic ulcer complications if oral medicine cannot be provided.

Keyphrases

helicobacter pylori
end stage renal disease
ejection fraction
helicobacter pylori infection
chronic kidney disease
risk factors
prognostic factors
peritoneal dialysis